Management team

Jonathan Emms was appointed to the Board as Chief Operating Officer on 2 September 2019 and became Chief Executive Officer in January 2025.

Jonathan brings significant senior-level experience of the global pharmaceutical industry to the Group. Previously, he was Chief Commercial Officer for Pfizer’s Internal Medicines organisation, where he led commercial activities across the company’s global operations.

He held a number of senior positions at Pfizer, including Head of Marketing for its Global Established Pharmaceutical Business and Head of Marketing for Specialty Care, Europe, and oversaw the UK launch of Spiriva® under the company’s co-promotion agreement with Boehringer Ingelheim. He was also Country Manager in the UK, Pfizer’s largest affiliate outside the United States, where he had responsibility for manufacturing, research and commercial operations and during his tenure was elected President of the Association of the British Pharmaceutical Industry (ABPI).

Prior to his time at Pfizer, Jonathan held several roles of increasing responsibility at GSK, where he gained significant respiratory experience, including leading the UK launch of Serevent® in COPD. He holds a BSc in Materials Technology from Coventry University, UK.

Sarah Duncan was promoted to Chief Financial Officer of NIOX on 14 May 2025.

She joined the company in 2018 as Group Finance Manager and took on the additional role of Company Secretary in November 2020.

Sarah was promoted to Group Financial Controller in April 2024, having contributed to the Group’s financial management, reporting, and governance functions over several years. She brings solid experience in finance and compliance and continues to play a key role in supporting the Group’s operations and strategic objectives.

She holds a BA in Business and Information Management from the University of Sheffield and is a member of the Institute of Chartered Accountants of England and Wales.

Tom Scaccia joined the Group in 2017 and brings 20+ years of extensive senior pharmaceutical/device leadership experience. His most recent responsibility was leading the US Pharmaceuticals Business Unit. Previously, he led Strategic Marketing for the entire US Asthma portfolio at GlaxoSmithKline. Additionally at GSK, he had a progressive, award-winning career of leading teams in sales, marketing, business development, organizational alignments, strategic planning and execution. Prior to joining GSK, he established a Medical Billing / Consulting company that became a US regional leader in improving health insurance reimbursement through enhanced business acumen and operational procedures.

Warren joined the Group in January 2019 and brings over 20 years of commercial experience from across local and International markets.

Covering mainstream pharmaceuticals, rare disease and medical devices, Warren has developed his experience through positions in marketing, commercial and business operations at Sanofi, MSD and Jazz Pharmaceuticals. More recently, Warren held the position of Head of Partner Markets at EUSA Pharma before joining the Company to lead the Rest of the World Partner Business.

Warren holds a BSc (Hons) majoring in Chemistry combined with Mathematics from the University of Hertfordshire.

George Yu joined the Group in March 2021 and he brings more than 15 years experience in the Medical Devices business in China and APAC.

Previously, George worked for Teleflex Medical China and ConvaTec Medical China, where he held business unit director positions with full P&L responsibilities and achieved significant growth. In his earlier career in medical device, George worked for Johnson & Johnson Medical for 8 years, starting as an International Management Trainee, and then holding different positions with increasing responsibilities including sales management, marketing and APAC regional marketing.

George graduated from Shanghai Jiaotong University, and obtained his MBA from the University of Rochester in the US.

Born and raised in Uppsala in Sweden, Jan has worked for large and small global companies throughout his career. With 35 years of experience in Supply Chain, Jan has worked for Pharmacia for 11 years and then Pfizer for another 11 years. Following this, Jan spent a year with Kuehne & Nagel, one of the largest forwarding agents in the world until 2008 following which he started working for Aerocrine.

Following the acquisition of Aerocrine, Jan has continued to lead the Group’s Supply Chain and Technical Operations team to the present day.

Rebecca Clayton-Wherity joined the company in 2019 as UK Financial Controller before expanding her responsibilities to include EMEA and APAC. In April 2024 she was appointed Group Operating FD, overseeing financial operations and governance across the global business. In May 2025 she additionally took on the role of Company Secretary.

Prior to joining NIOX Rebecca spent almost 12 years at PwC where she qualified as a Chartered Accountant. She holds a degree in English Literature from Newcastle University.

Jodie joined the company in 2021 as HR Manager for the EMEA region and expanded her responsibilities to include the US in 2022. Following her promotion to Senior HR Manager in January 2025, Jodie was appointed as Global Director of Human Resources in 2026 and now leads the company’s global HR strategy and people function.

Prior to joining the company, Jodie built 19 years of experience in human resources across both public and private sector organisations, developing broad expertise in people management, organisational development, and HR leadership.

Jodie holds a Postgraduate Diploma in Human Resources Management and is a member of the Chartered Institute of Personnel and Development (CIPD).